

Mihaly Cserepes

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9487118/mihaly-cserepes-publications-by-citations.pdf>
Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8 papers	204 citations	7 h-index	8 g-index
8 ext. papers	239 ext. citations	8 avg, IF	2.13 L-index

#	Paper	IF	Citations
8	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 738-746	8.9	63
7	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. <i>European Journal of Cancer</i> , 2014 , 50, 1819-1828	7.5	57
6	Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. <i>Journal of Controlled Release</i> , 2017 , 261, 287-296	11.7	48
5	P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b. <i>Cells</i> , 2020 , 9,	7.9	11
4	A user-friendly, high-throughput tool for the precise fluorescent quantification of deoxyribonucleoside triphosphates from biological samples. <i>Nucleic Acids Research</i> , 2020 , 48, e45	20.1	9
3	Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein-Expressing Cells. <i>Cancer Research</i> , 2020 , 80, 663-674	10.1	8
2	KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. <i>Oncotarget</i> , 2016 , 7, 79503-79514	3.3	8
1	EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. <i>Cancers</i> , 2022 , 14, 2407	6.6	0